Financial Release TSPC FY 2024.pdf

The aforementioned Tempo Scan's FY'2024 consolidated net sales performance major
benefactors were as follows:

1) Tempo Scan's Pharmaceutical division was able to sustain its net sales
stellar growth which grew high double digits by 16.90 and amounted
to Rp.4,746.8 billion, such net sales growth was significantly higher when
compared to its net sales growth in previous year whereas this division net sales
only grew by 12.490.

This division net sales growth main benefactor continued to be its Consumer
Health products group which net sales increased significantly by 17.19
and amounted to Rp.4,669.5 billion. This Consumer Health group's
commendable net sales increase was propelled by its Nutritional products' net
sales which has risen substantially by 35.490 year on year. The said
Nutritional products rapid sales growth occurred on a nationwide basis as
Consumers demand surged substantially across all sales channels and
geographical areas. While similar positive net sales performance was also
exhibited by the Consumer Health group's OTC and Vitamins products which net
sales increased by 2.7Yo, despite the overall OTC market challenging condition
which amongst others caused by regulatory hurdle.

Moving ahead, Tempo Scan is continuously monitoring consumers slowing
demand which corresponded to weaker buying power started from lower income
group and gradually expanded to the middle income group, and such a condition
has trigger precipitous price discounting and eventually permanent price
reductions in the FMCG, pharmaceutical and even nutritional products categories
as competitive pressure was intensifying especially toward year end 2024.

In addition, Tempo Scan Pharmaceutical division Prescription Medicine products'
net sales had increased by 3.196 and amounted to Rp.77.4 billion. Therefore, for
FY'2024 Tempo Scan's Consumer Health products group and its Prescription
Medicines group net sales contributions toward its Pharmaceutical division's total
net sales were 98.4Y4 and 1.6Y4 respectively.

On the other hand, the Pharmaceutical division's international business net sales
had faced a headwind particularly in its West Africa market, however its Malaysia
market net sales grew positively, and in aggregate such international business had
declined by 8.3Yo and amounted to Rp.264.6 billion. Such a net sales result was
lower compared to its net sales in the previous year which grew by 21.6Y6.
Conseguently, the aforementioned Pharmaceutical international business' net
sales contribution towards Tempo Scan's Pharmaceutical division total net sales
was 5.6Yo or lower when compared to its net sales contribution of 7.1Y6 in
previous year.

2) Tempo Scan's Consumer Products & Cosmetics (“CPC”) division has also
been able to register a healthy net sales growth which increased by
10.670 and amounted to Rp.4,556.4 billion. This division's net sales main
benefactor continued to be its Consumer Products group which net sales increased
commendabiy by 10.996 and amounted to Rp.3,656.7 billion. While its Cosmetics
group's net sales performance had continued to deliver an excellent growth rate
of 9.3Yo and amounted to Rp.899.7 billion despite industry wide weaker demand.

The Consumer Products group's core brand eguities have dominant market
positions, henceforth these brands' products are well poised to face the FMCG
market malaise related to the consumers demand weakness. There were several
major FMCG companies have become despaired and engaged in a massive
discount war to cut their products price in order to recover their products dwindling
market shares.

Moreover, the CPC division's Consumer Products group and Cosmetics group net
sales contributions toward this division total net sales were 80.3Y6 and 19.7Yo
respectively for FY"2024, such a contribution was practically unchanged when
compared to these net sales contributions in previous year which were at 80.0Y6
and 20.0Y4 respectively.

For FY'2024, the CPC division's international business net sales was able to
maintained its robust growth and registered a significant net sales increase of
15.899. Such a strong net sales performance was contributed primarily by
its Thailand and Philippines markets whereby both of its Consumer
Products and Cosmetics which aggregate net sales have increased by
37.2Y0 and 10.9”o respectively. Conseguently, this CPC division's
International Business net sales contribution towards its total net sales had
increased to become 4.3Y6 versus its net sales contribution in FY'2023 which stood
at 4.1Yo.

3) Tempo Scan's Distribution division net sales declined by 11.9Y6 and amounted to
Rp.4,351.3 billion. Its main contributor of this division net sales growth was its
Non-Pharma Principals' products which net sales had decreased by 14.0Yo and
amounted to Rp.3.903,1 billion, while on the other hand this division Pharma
Principals' products registered an increase of 12.7Yo and amounted to Rp.448.2
billion. Correspondingly, the aforesaid Non-Pharma Principals' products and
Pharma Principals' products net sales contributions toward the Distribution division
total net sales stood at 89.7Yo and 10.3Yo respectively, such a contribution was
marginally changed when compared to these net sales contributions in previous
year which were at 91.996 and 8.1Yo respectively.

Furthermore, for FY'2024 Tempo Scan's gross profit result registered a
significant increase of 10.1”o and amounted to Rp.5,177.5 billion, such an
increase was significantly higher compared to its net sales growth rate, hence as a
result its gross profit margin had also increased significantly to become
37.9Yo versus its gross profit margin in the previous year which was
35.8Yo.

Such a gross profit margin increase was attributed amongst other to its business mix
change, whereas for FY"2024 Tempo Scan Pharmaceutical and CPC divisions net sales
contribution have risen considerably to become 68.1Yo of Tempo Scan's consolidated
net sales. These 2 divisions have generated significantly higher gross profit margin
VIS-a-vis its Distribution division which net sales contribution has also declined and
generated much lower gross profit margin.

Moving on to Tempo Scan's total operating expenses for FY'2024, it has decreased by
7.0Yo and amounted to Rp.3,368.7 billion, such a decrease was contributed amongst
others by its total selling expenses that had decreased by 1.896 and amounted to
Rp.2,784.0 billion. Conseguenttly, its total selling expenses as a ratio to Tempo Scan's
consolidated net sales was 20.4Y4 or lower compared to previous year whereas such
ratio was still at 21.6Yo.

On the other hand, its total general administrative expenses increased by 13.1Y6 and
amounted to Rp.695.5 billion, therefore the aforesaid total general administrative
expenses ratio towards Tempo Scan's consolidated net sales was 5.1Y6 or higher when
compared to the same ratio in previous year which was 4.7Y9.

Moreover, Tempo Scan's net other operating income had considerably increased by
164.0Yo and positively amounted to Rp.110.8 billion, such a sharp increase was a
sharp contrast if compared to previous year net other operating income which was
negative by Rp.173.0 billion. The aforementioned net positive amount was
predominantly contributed by its foreign currencies reserved fund substantial gain.

Commensurately with the above result, Tempo Scan's operating profit for
FY'2024 managed to deliver a sharp increase of 67.5Yo and amounted to
Rp.1,808.9 billion, henceforth its operating profit margin has also increased
to become 13.2”/o which was a robust increased when compared to previous
year whereas its operating profit margin was only at 8.20.

Furthermore, for FY'2024 its net non-operating income had decreased and amounted
to Rp.126.7 billion or lower compared to previous year which amount was Rp.523.3
bilion. However, such a decrease was mainly attributed to the one-time gain
registered from non core asset divestment in FY'2023.

As the result, Tempo Scan's FY'2024 net profit after tax had increased sharply
by 23.07/o and amounted to Rp.1,447.7 billion, conseguently its net profit after
tax margin stood at 10.6Yb or significantly higher versus its net profit after tax margin
in the previous year which was only 9.0Y6.

Commensurately with the above, Tempo Scan's EBITDA had robustiy surged by
60.60 and amounted to Rp.2.251,7 billion, conseguently its EBITDA margin
for FY'2024 had also risen to 16.5Yo or sharply higher compared to its
EBITDA margin in previous year which was only 10.70. e

As pertained to Tempo Scan's balance sheet position as of 31 December 2024, it
remained solid whereas its cash and cash eguivalent position total amount stood at
Rp.4,456.6 billion or a substantial increase of 20.6Yo compared to previous year. In
addition, its net operating cycle was at 74 days despite the extremely challenging
market condition. Furthermore, Tempo's Scan total assets and shareholders'
eguity were amounted to Rp.12,489.2 billion and Rp.9.150,8 billion

respectively.

Tempo Scan's Board of Directors would like to express our highest appreciation to all
Tempo Scan's Board Commissioners, its management team and all of its employees
for their continuous support, advise, dedication, commitment and hard works. As well
as to our valued shareholders, business partners, vendors, customers and professional
parties that has made Tempo Scan can achieved the abovementioned financial
results.

Jakarta, 25 March 2025
On behalf of PT. Tempo Scan Pacific, Tbk.

pe
Liza Prasodjo

Chief Financial Officer

Copies:
- Mr. Handojo S. Muljadi, Tempo Scan's Executive Chairman
- Tempo Scan's Board of Directors